Development of new predictive markers for endocrine therapy and resistance in breast cancer

Henriksen, Katrine L; Sonne-Hansen, Katrine; Kirkegaard, Tove; Frogne, Thomas; Lykkesfeldt, Annè E.

doi:10.1080/02841860802026993

Cited by 7 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A longstanding research field has focused on identifying predictive markers of tamoxifen resistance [5–7] . Most recently, modification of tamoxifen’s effectiveness by functional variants in the enzymes that activate and deactivate the parent drug, or by inhibition of these enzymes by other prescription drugs, has received a lot of attention in the evolution of tamoxifen personalization [8,9].…”

mentioning

confidence: 99%

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes

Cronin‐Fenton

Lash

2011

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Adjuvant tamoxifen therapy of breast cancer patients with estrogen receptor-positive tumors reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen is metabolized by several polymorphic enzymes, including cytochrome P450 2D6 (CYP2D6), to more active metabolites. We have reviewed the clinical pharmacology of tamoxifen and evaluated the evidence from clinical epidemiology studies regarding the association between CYP2D6 inhibition and tamoxifen effectiveness. We conclude that the impact of CYP2D6 inhibition on tamoxifen effectiveness is likely to be null or small, at least in the populations studied so far. Understanding the effect of variations in tamoxifen metabolism on breast cancer outcomes, if any, will likely require a broader perspective, including examination of the complete metabolic pathway and subgroups of patients with other markers of potentially poor tamoxifen response.

show abstract

mentioning

confidence: 99%

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes

Cronin‐Fenton

Lash

2011

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

show abstract

“…However, there is only a slight indication of increased estrogen receptor levels in nonneoplastic tissue in breast cancer cases (15). Moreover, the expression of these hormone receptors does not always imply a response to treatment with anti-estrogens and patients who experience response at first may become resistant after prolonged treatment (16). It might well be that tissue-specific hormone actions and local hormone concentrations are more relevant than hormonal levels in the peripheral circulation.…”

Section: Breast Cancermentioning

confidence: 94%

Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones

Mueller

Gooren

2008

European Journal of Endocrinology

115

View full text Add to dashboard Cite

Objective: To assess the risk of development of hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Design: Description of cases of transsexuals who have developed a hormone-related malignancy observed in their own clinic or reported in the literature. Recommendations for early diagnosis and prevention are presented. Methods: Review of the literature in PubMed. Results: In male-to-female transsexuals receiving estrogen administration, lactotroph adenomas, breast cancer, and prostate cancer have been reported. In female-to-male transsexuals receiving treatment with testosterone, a single case of breast carcinoma and several cases of ovarian cancer have been reported. So far endometrial cancer has not been encountered though it remains a potential malignant development. Conclusions: There are so far only a few cases of hormone-related cancer in transsexuals. There may be an underreporting. The probability of a hormone-related tumor increases with the duration of exposure to cross-sex hormones and the aging of the population of transsexuals.

show abstract

“…The use of metformin (dimethylbiguanide) in such patients helps to avoid the effect of primary resistance to aromatase inhibitors. Little is known about the molecular targets of the proapoptotic action of COX-2 inhibitors, although in a number of cases in apoptotic cells a violation of phosphorylation of kinase Akt (Protein kinase B alpha) has been noted [29].…”

Section: Case Studymentioning

confidence: 99%

Antioxidant Modulation of Hematological Toxicity during Chemotherapy for Breast Cancer

Mohammad¹,

Бондаренко²,

Zavizion³

et al. 2017

J Cytol Histol

View full text Add to dashboard Cite

Side effects of anticancer drugs seriously limit the achievement of the maximum therapeutic effect of the most cytostatic. One of the pathophysiological bases of side effects is the ability of cytotoxic agents to intensify the freeradical processes and the consequent lipid peroxidation (LPO) in the cell membranes of various organs. When the antitumor treatment is conducted, the antioxidant enzyme deficiency increases, there is the depletion of nonenzymatic and enzymatic mechanisms of oxidation protection units, resulting in a reduction of organism resistance and damage to vital organs and systems. In this connection it is important to study the possibility of correction of violations occurring in cancer patients with drugs with antioxidant action type.Classic example of breast cancer individualization treatment is by determining of reproductive hormones and epidermal growth factor [8]. Prognostic value of ER and PR determination for endocrine therapy is confirmed by meta-analysis of 55 randomized trials with 37000 breast cancer patients. It is proved that ER expression in breast tumor indicates potential responsiveness to drug treatment, this is aimed to remove estrogens source and its effect recovering. PR is the first step in cell reaction to progestines and it determines cell responsiveness to some drugs, but mainly because it synthesis in breast cancer cells is prompt by estrogens. Presence of PR confirms ER functional activity. Breast cancer patients who has both or at least one of steroid hormones receptors have more favorable prognosis than those has no receptors. Thus 75% of patients with both positive receptors responses effectively to endocrine therapy and 50% with only ER positive receptor. However there was response to endocrine therapy in 10% of patient with both negative receptors [9].A high level of estrogen receptors is associated, in front of all, with an increase in overall and not relapse-free survival, and is a predictor of the effectiveness of hormone therapy. In recent years Ki-67 proliferation index has been used to predict the effectiveness of treatment [10]. The panel of estrogen progestin receptor markers, Her2/neu and Ki-67, is today standard both at the stage of primary diagnosis and in morphological studies in the course of treatment. Taking into account these four markers, the main immunomorphologic subtypes of breast cancer are listed above. In the case of neoadjuvant treatment or treatment of metastatic cancer (if there is a possibility of re-biopsy in the dynamics), Ki-67 has recently been used as a marker for the effectiveness of treatment. Repeated biopsy is performed after 3 weeks of treatment. Decrease of marker level is the first morphological

show abstract

Development of new predictive markers for endocrine therapy and resistance in breast cancer

Cited by 7 publications

References 22 publications

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes

Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones

Antioxidant Modulation of Hematological Toxicity during Chemotherapy for Breast Cancer

Contact Info

Product

Resources

About